claim: peptide vaccine candidate mimics the heterogeneity of natural sars-cov-2 immunity in convalescent humans and induces broad t cell responses in mice models
evidence_1: vaccine peptides were selected based on their frequency as hla class i and class ii personal epitopes (pepis) restricted to multiple autologous hla alleles of individuals in an in silico cohort of 433 subjects of different ethnicities.", "in addition, polypepi-scov-2-specific, polyfunctional cd8+ and cd4+ t cells were detected ex vivo in each of the 17 asymptomatic/mild covid-19 convalescents blood investigated, 15 months after symptom onset.", "polypepi- scov-2 vaccine administered with montanide isa 51vg adjuvant generated robust, th1-biased cd8+ and cd4+ t cell responses against all four structural proteins of the virus, as well as binding antibodies upon subcutaneous injection into balb/c and cd34+ transgenic mice."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )